DrugCendR begins CEND1-001 trial for pancreatic cancer
DrugCendR has started the Phase l CEND1-001 trial to examine the safety, tolerability, and biologic...
DrugCendR has started the Phase l CEND1-001 trial to examine the safety, tolerability, and biologic...